3.42

8.23% 0.26

After Hours: 3.44 0.02 +0.58%

Camp 4 Therapeutics Corp (CAMP)

Overview News Price History Option Chain Financials Why CAMP Down? Discussions Forecast Stock Split

Camp 4 Therapeutics Corp stock is traded at $3.42, with a volume of 336.70K. It is up +8.23% in the last 24 hours and down -18.57% over the past month. Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.

Previous Close:

$3.16

Open:

$3.28

24h Volume:

336.70K

Relative Volume:

1.84

Market Cap:

$177.59M

Revenue:

$3.50M

Net Income/Loss:

$-80.40M

P/E Ratio:

-1.3302

EPS:

-2.5711

Net Cash Flow:

$-29.83M

1W Performance:

+3.01%

1M Performance:

-18.57%

6M Performance:

-10.70%

1Y Performance:

+88.95%

1-Day Range:

$3.16

$3.58

1-Week Range:

$2.90

$3.58

52-Week Range:

$1.32

$7.75

Camp 4 Therapeutics Corp Stock (CAMP) Company Profile

Name

Camp 4 Therapeutics Corp

Sector

Healthcare (1074)

Industry

Biotechnology (599)

Phone

617-651-8867

Address

ONE KENDALL SQUARE, CAMBRIDGE, CA

Employee

Twitter

@calamp

Next Earnings Date

2026-08-13

Latest SEC Filings

CAMP's Discussions on Twitter

Compare CAMP vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CAMP Camp 4 Therapeutics Corp	3.42	164.09M	3.50M	-80.40M	-29.83M	-2.5711
VRTX Vertex Pharmaceuticals Inc	479.00	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	667.17	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	888.82	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	188.07	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	278.40	36.28B	4.29B	577.22M	641.34M	4.2086

Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-14-26	Initiated	Rodman & Renshaw	Buy
Oct-02-25	Initiated	Cantor Fitzgerald	Overweight
Sep-16-25	Downgrade	JP Morgan	Overweight → Neutral
May-27-25	Initiated	Wedbush	Outperform
Nov-05-24	Initiated	JP Morgan	Overweight
Nov-05-24	Initiated	Piper Sandler	Overweight
Nov-05-24	Initiated	William Blair	Outperform
Aug-16-22	Upgrade	Craig Hallum	Hold → Buy
Dec-22-21	Downgrade	Craig Hallum	Buy → Hold
Sep-24-21	Reiterated	Craig Hallum	Buy
Jun-25-21	Reiterated	Craig Hallum	Buy
Dec-18-20	Downgrade	JP Morgan	Neutral → Underweight
Apr-17-20	Upgrade	Jefferies	Hold → Buy
Mar-05-20	Reiterated	Craig Hallum	Buy
Dec-20-19	Reiterated	Craig Hallum	Buy
Dec-20-19	Downgrade	First Analysis Sec	Outperform → Neutral
Jun-28-19	Upgrade	Northland Capital	Market Perform → Outperform
May-29-19	Downgrade	Goldman	Neutral → Sell
May-01-19	Reiterated	Craig Hallum	Buy
Mar-25-19	Downgrade	JP Morgan	Overweight → Neutral
Jan-25-19	Upgrade	JP Morgan	Neutral → Overweight
Dec-21-18	Upgrade	Craig Hallum	Hold → Buy
Dec-14-18	Reiterated	B. Riley FBR	Buy
Dec-11-18	Downgrade	First Analysis Sec	Strong Buy → Outperform
Dec-11-18	Downgrade	Northland Capital	Outperform → Market Perform
Nov-27-18	Initiated	Goldman	Neutral
Oct-15-18	Initiated	Jefferies	Hold
Sep-28-18	Reiterated	Craig Hallum	Hold
Apr-27-18	Reiterated	Craig Hallum	Hold
Mar-08-18	Downgrade	Craig Hallum	Buy → Hold
Feb-16-18	Upgrade	First Analysis Sec	Equal-Weight → Overweight

View All

Camp 4 Therapeutics Corp Stock (CAMP) Latest News

04:15 AM

CAMP4 THERAPEUTICS CORPORATION (CAMP) Stock Forecasts - Yahoo! Finance Canada

04:15 AM

09:00 AM

Camp4 Therapeutics’ lead ASO approved for clinical trials in Australia - BioWorld News

09:00 AM

07:38 AM

CAMP4 receives Australian clearance for SYNGAP1 therapy trial - Investing.com Australia

07:38 AM

07:25 AM

Camp4 Therapeutics Corp secures clinical trial approval for first SYNGAP1 disease-modifying therapy in Australia - Traders Union

07:25 AM

07:02 AM

CAMP4 Therapeutics (CAMP) clears CMP-002 trial in Australia, eyes $50.1M raise - Stock Titan

07:02 AM

07:00 AM

SYNGAP1 Disorder Has No Approved Treatments; CAMP4 Clears Trial - Stock Titan

07:00 AM

04:11 AM